Greetings
Through Strategic Focus and Innovation,
KDDF is committed to advancing Korea’s pharmaceutical and biotechnology industry.
Welcome to the Korea Drug Development Fund.
I am Yeong Min Park, CEO of the Korea Drug Development Fund (KDDF).
Through sustained investment in drug discovery and innovation, Korea’s pharmaceutical and biotechnology industry has developed research and development capabilities of global caliber. Building on this progress, Korea continues to strengthen the foundation needed to emerge as a global leader in the pharmaceutical and biotechnology sector.
At the same time, persistent uncertainty in the global economy, a slowdown in investment, and challenges throughout the commercialization process continue to create a demanding environment for drug development. Under these circumstances, strategic government support and systematic program management are more important than ever to ensure that promising R&D projects can advance without interruption and ultimately deliver tangible outcomes.
In line with Korea’s national goal of becoming one of the world’s top five pharmaceutical and biotechnology leaders, KDDF will continue to expand its investment in and support for innovative drug development pipelines. We will also work proactively to address bottlenecks at each stage of development, helping research achievements progress into clinical development, commercialization, and ultimately, global success.
To fulfill this mission, KDDF will pursue its initiatives based on four core values.
First, Scientific Rigor.We will carefully assess the scientific validity and credibility of each pipeline based on robust evidence and expert evaluation. Through systematic and stage-appropriate support, we will help high-potential R&D projects advance successfully.
Second, Collaboration and Openness.We will strengthen partnerships with experts, research institutions, companies, and related organizations in Korea and abroad. By promoting open innovation, we will continue to expand collaboration across the drug development ecosystem.
Third, Ethical Responsibility.We will operate our programs in accordance with fair standards and transparent procedures, while further strengthening the accountability and trust required of a national R&D initiative.
Fourth, Contribution to Society.Through the development of innovative medicines, we will contribute to improving public health. At the same time, we will create economic and industrial value that supports the sustainable growth of Korea’s pharmaceutical and biotechnology industry.